BostonGene Corporation today announced that two abstracts were selected for presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.
“As part of our commitment to improving patient outcomes, we remain focused on further developing our innovative analytical tools to understand the composition and activity of the tumor and its microenvironment,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene. “We look forward to presenting robust data at the American Society of Hematology Annual Meeting and Exposition demonstrating the critical need for molecular and immune profiling and analytics to advance precision medicine for cancer patients.”
Details of the presentations are below:
Title: Integrated Genomic and Transcriptomic Analysis Provides Molecular Characterization of Distinct Clonal Evolution Pathways during Follicular Lymphoma Transformation
Abstract Number: 2973
Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster II
Time and Location: Sunday, December 11 | 6:00 PM-8:00 PM, Hall D
Presenter: Kevin Ferguson, MD, Western Diagnostic Services Laboratory
Research conducted by Pacific Central Coast Health Centers at Dignity Health, Mission Hope Medical Oncology, Western Diagnostic Services Laboratory and BostonGene.
This presentation demonstrates the utility of integrated genomic and transcriptomic methods in elucidating clonal evolution during transformation of real-world cases of patients with follicular lymphoma, potentially leading to earlier identification of high-risk FL subsets and the improvement of personalized treatment options.
Title: Correlative Biomarkers for CART19 Response in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Abstract Number: 4159
Session: Session: 621. Lymphomas: Translational—Molecular and Genetic: Poster III
Time and Location: Monday, December 12 | 6:00 PM-8:00 PM, Hall D
Presenter: Connie Lee Batlevi, MD, PhD, Memorial Sloan Kettering Cancer Center
Research conducted by Memorial Sloan Kettering Cancer Center and BostonGene.
In this study, whole-exome sequencing (WES) and RNA sequencing (RNA-seq) were used to identify potential biomarkers of response to CART19 cellular therapy in patients with DLBCL, underscoring the role of integrative molecular analysis to improve personalized treatment recommendations.
In addition to the poster presentations, the abstracts have been published online in the November supplemental issue of “Blood.”
For more information, please visit the 64th ASH Annual Meeting and Exposition website at https://www.hematology.org/meetings/annual-meeting/abstracts.
About BostonGene Corporation
BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor Portrait™ Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor Portrait™ Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221202005340/en/
Source: BostonGene Corporation
View this news release online at:
http://www.businesswire.com/news/home/20221202005340/en
